| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
|
J Clin Oncol
|
2003
|
17.67
|
|
2
|
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).
|
Qual Life Res
|
2011
|
9.24
|
|
3
|
Development and validation of a prognostic index for 4-year mortality in older adults.
|
JAMA
|
2006
|
6.79
|
|
4
|
Age and acute myeloid leukemia.
|
Blood
|
2006
|
6.46
|
|
5
|
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
5.75
|
|
6
|
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
|
Blood
|
2001
|
5.20
|
|
7
|
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.
|
Blood
|
2008
|
4.66
|
|
8
|
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
|
Blood
|
2015
|
2.43
|
|
9
|
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.
|
Blood
|
2006
|
2.01
|
|
10
|
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
|
Blood
|
2014
|
1.72
|
|
11
|
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
|
Leuk Res
|
2008
|
1.45
|
|
12
|
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
|
J Clin Oncol
|
2011
|
1.29
|
|
13
|
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
|
Blood
|
2016
|
1.05
|